Skip to content

Disc Medicine IRON Free cash flow

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.29B+66.4%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$49.16M-139%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$119.69M-6.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$130.75M-22.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's free cash flow?
Disc Medicine (IRON) reported free cash flow of -$62.24M in Q1 2026.
How has Disc Medicine's free cash flow changed year-over-year?
Disc Medicine's free cash flow decreased by 47.4% year-over-year, from -$42.23M to -$62.24M.
What is the long-term trend for Disc Medicine's free cash flow?
Over 3 years (2022 to 2025), Disc Medicine's free cash flow has grown at a 62.3% compound annual growth rate (CAGR), from -$42.4M to -$181.33M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.